BrainQuant SA is a Swiss neuroimaging spin-off from the Wyss Center for Bio and Neuroengineering, co-founded with EPFL, Universite de Geneve, and HCK Healthcare Konnect. The company develops AI-powered software for the early detection and differential diagnosis of neurodegenerative diseases using MRI-based arterial spin labeling (ASL) sequences.

The platform analyzes ASL MRI data to reveal subtle changes in cerebral blood flow that often precede visible structural brain damage. By extending routine structural MRI to include functional perfusion information, BrainQuant provides a non-invasive, radiation-free alternative to FDG-PET scans, which require separate imaging appointments and radioactive tracer injection. Proprietary machine learning algorithms process the ASL data to generate clinically actionable diagnostic outputs.

BrainQuant targets clinical neurologists and neuroradiologists managing patients with suspected cognitive decline, including Alzheimer's disease and other dementias. The system is designed to integrate into existing MRI clinical workflows as an add-on sequence, supporting early biomarker detection and differentiation between dementia subtypes. The company was launched in 2025 and is preparing for market entry in Europe and the United States.